AUTHORS
Jingjing Feng, Mi Shao2, Heng Cao3, Mingming Zhang, PhD4, Xintong Feng5, Ming Chen6, Shan Fu7, Guoqing Wei8, Ruimin Hong9, Lianjun Shen, MD10, Jin Lin11, Zhihong Liu12, Jia Liu13, Yongxian HU, MD14, He Huang, PhD15
AFFILIATIONS
1 Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
3 Department of Rheumatology of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
4 Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
5 Gracell Biotechnologies Ltd & Cell therapy, AstraZeneca, Shanghai, China
6 Biometrics and Data Science, R&D China, AstraZeneca, Shanghai, China
7 Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
8 Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
9 Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
10 Gracell Biotechnologies Ltd & Cell therapy, AstraZeneca, Shanghai, China
11 Department of Rheumatology of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
12 Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
13 Gracell Biotechnologies Ltd & Cell therapy, AstraZeneca, Shanghai, China
14 Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
15 Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
ABSTRACT
Background: Refractory systemic lupus erythematosus (rSLE) is driven by abnormally activated B cells and long-lived plasma cells that produce autoantibodies. GC012F is a CD19/BCMA dual-targeted CAR-T cell therapy manufactured using a proprietary manufacturing process (FasTCAR platform). We report the long-term safety, efficacy, and cell kinetic data from a phase 1 trial (NCT05846347) of GC012F in rSLE. The median follow-up was more than two years.
Methods: This was an open-label, single-arm phase 1 trial enrolling rSLE patients who did not respond to ≥2 immunosuppressants and ≥1 biologic. After lymphodepletion, patients received a single GC012F infusion (1, 2, or 3 × 105 CAR+ T cells/kg). Primary endpoints were the proportion of patients with dose-limiting toxicities (DLTs) within 28 days and adverse events (AEs) within 12 weeks post-infusion. Secondary endpoints included the proportion of patients achieving DORIS remission, LLDAS, and SRI-4 responses within 24 weeks. We also assessed CAR-T cell expansion and persistence in peripheral blood and bone marrow, as well as target organ responses.
Results: As of April 15, 2026, 15 rSLE patients were enrolled (3 in DL1, 3 in DL2, 9 in DL3). The median age was 28 years (range: 22–55 years); 14 patients (93.3%) were female and 1 patient (6.7%) was male. All 15 patients (100%) were Chinese. The median disease duration was 7.3 years (range: 1.3–23.7 years), and the median baseline SLEDAI-2K score was 12 (range: 6–26). Lupus nephritis (LN) was present in 73.3% of patients. GC012F was successfully manufactured for all 15 patients. The median follow-up was 884 days (range: 674–1024 days).
Primary safety endpoints: No DLTs occurred within 28 days post-infusion across all dose groups. AEs within 12 weeks were manageable. Cytokine release syndrome (CRS) occurred in 14/15 patients, with 12 experiencing grade 1 CRS. Two patients in the high-dose group developed grade 3 CRS, both of whom recovered rapidly following corticosteroid treatment. One case of reversible grade 2 ICANS occurred. During the ≥2-year follow-up, no late-onset AEs or secondary malignancies were observed. Eight patients had a total of 11 episodes of grade 1-2 infections. No grade ≥3 or opportunistic infections occurred.
Secondary kinetic and immune reset endpoints: GC012F expanded successfully in 100% (15/15) of patients. The median Tmax was 10 days in peripheral blood and 28 days in bone marrow. By week 48, peripheral blood CAR gene copies fell below the limit of detection (qPCR) in all patients. Flow cytometry confirmed CAR-T cell levels had dropped to background (<1 cell/μL). This status remained stable until week 96. B cells were completely depleted after infusion, with a median recovery time of 56 days. At week 96, IgM, IgG, and IgA levels returned to normal in 9/11, 6/11, and 5/11 patients, respectively. Autoantibodies became undetectable and complement levels normalized.
Secondary efficacy and organ protection endpoints: Disease activity decreased significantly and durably. Median SLEDAI-2K scores dropped from 12 at baseline to 4 at week 4, and to 0 at week 96. Based on NRI evaluation, during follow-up, 86.7% (13/15) and 80.0% (12/15) of patients achieved LLDAS and DORIS remission, respectively, at least once. At week 24, the rates of LLDAS and DORIS remission were both 33.3% (5/15). By week 96, both LLDAS and DORIS remission rates remained stable at 53.3% (8/15), with remission sustained from week 48, achieving long-term drug-free remission. Regarding target organs, all 7 patients with severe baseline proteinuria (>0.5 g/d) showed major reductions in urine protein. Four of them achieved normal urine protein (<0.2 g/d) or complete renal remission. Among 4 patients with impaired baseline kidney function, 3 patients had increases in eGFR ranging from 25% to 42% at week 96. The other patient with severe impairment remained stable.
Conclusion: GC012F successfully met its primary safety endpoints. No DLTs occurred, and early AEs were highly manageable. Cell manufacturing and in vivo expansion achieved a 100% success rate. Patients achieved excellent early clinical remission (DORIS/LLDAS), which was maintained during long-term follow-up. Target organ damage was reversed, and kidney function was effectively protected.
DISCLOSURES
Jingjing Feng: No relevant conflicts of interest to declare.